NICE is an NHS organisation that provides a range of different guidance and recommendations to the NHS on high quality care. All Diabetes and Endocrinal, Nutritional and metabolic conditions Guidelines can be accessed from the NICE website. www.nice.org.uk
Chronic Kidney Disease (CG73): Early indentification and management of chronic kidney disease in adults in primary and secondary care
Coeliac Disease (CG86): Recognition and assesment of coeliac disease. Children and adults
Dapagliflozin in combination therapy for treating type 2 diabetes (TA 288)
Depression (CG23): Management of depression in Primary and secondary care
Depression (CG28): Depression in children and young adults
Diabetes in Pregnacy (CG63): Management of diabetes and its complications from Pre-conception to post natal period
DIABETES TYPE 1: Children , young people and adults (CG15)
Diagnosis and management of type 1 diabetes in children, young people and adults.
DIABETES TYPE 1 and TYPE 2: Long acting insulin analogues (TA53)
The clinical effectiveness and cost effectiveness of long acting insulin analogues for diabetes.
DIABETES TYPE 1 and TYPE 2: Patient Education Models (TA60)
The clinical effectiveness and cost effectiveness of patient education models for diabetes
DIABETES TYPE 2: The management of type 2 diabetes (CG66)
DIABETES TYPE 2: Footcare (CG10)
Prevention and Management of Foot Problems.
DIABETES TYPE 2: The management of type 2 diabetes (CG87)
Management of type 2 diabetes
DIABETES TYPE1: Allogenic pancreatic islet cell transplantation
NICE has now issued full guidance to the NHS
DIABETES: Insulin Pump Therapy (TA151): Continuous subcutaneous insulin infusion for treatment of diabetes.
Diabetic foot problems: Evidence Update 33 (March 2013). This update provides a summary of selected new evidence relevant to NICE clinical guideline 119 'Inpatient management of diabetic foot problems' (2011).
Exercise referral schemes to promote physical activity (PH54) Public Health Guidelines.
Guidance on Exenatide (February 2012)
NICE has approved the use of exenatide in triple therapy regimens for patients with type 2 diabetes, in latest guidance.
Hypertension (CG34): Management of hypertension in Primary care
OBESITY: identification, assessment and management of overweight and obesity in children, young people and adults (CG189). This guideline updates and replaces section 1.2 of NICE clinical guideline 43 (published December 2006). It offers evidence-based advice on the care and treatment of obesity. New recommendations have been added about low-calorie and very-low-calorie diets, bariatric surgery and follow-up care. NICE Press release
OBESITY: Managing overweight and obesity among children and young people (PH47)
OBESITY: Four commonly used methods to increase physical activity (PH2)
Brief interventions in primary care, exercise referral schemes, pedometers and community-based exercise programmes for walking and cycling
OBESITY: Promoting Physical Activity: (PH13)
Intervention guidance on workplace health promotion with reference to physical activity.
OBESITY: The prevention, identification, assesment and management of overweight and obesity in adults and childrens (CG43)
Preventing type 2 diabetes: population and community-level interventions
(Evidence update 66). It is a summary of selected new evidence relevant to NICE public health guidance 35 ‘Preventing type 2 diabetes: population and community-level interventions’ (2011).
SMOKING Cessation Services- (PH10)
Nice have published guidelines on smoking cessation services in Primary Care, pharmacies, local authorities and workplaces, particularly for manual working groups, pregnant women and hard to reach communities.
SMOKING CESSATION Varenicline (TA123)
Varenicline /Champix is recommended as a possible treatment to help smokers who have siad they want to stop smoking
Brief interventions and referral for smoking cessation.
STATINS: Cardiovascular Disease Appraisal (No. 94)
Statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established CVD Includes data on diabetes.
STATINS: Hypercolesterolemia- Ezetimibe (TA132)
Ezetimibe for the treatment of primary(hetrozygous-familial and non- familal hypercholesterolaemia
STATINS: Lipid Modification (CG67)
Cardiovascular risk assessment and the modicication of blood lipids for the primary and secondary prevention of CVD
Type 2 diabetes: alogliptin (ESMN20)
Type 2 Diabetes: Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Type 2 Diabetes: Lixisenatide (ESNM26)
Vascular Disease - Clopidogrel and dipridamole(TA90) for the prevention of atherosclerotic events